Skip to main content

Advertisement

Table 5 Prognostic factors of PFS or OS

From: Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Factors PFS OS
Sex (male/female) 0.426 0.302
Age (61/<61) 0.706 0.084
CRP (1.5/<1.5) 0.654 0.832
Hemoglobin (12/<12) 0.351 0.435
Lymphocyte (%) (27/<27) 0.145 0.132
Lymphocyte (number) (1500/<1500) 0.488 0.900
CDCA1 CTL spots (2+/<2+) 0.004 0.870
CHD3 CTL spots (2+/<2+) 0.235 0.611
KIF20A CTL spots (2+/<2+) 0.486 0.840
CXCR3 + CCR4- T cells (8%/<8%) 0.046 0.966
CXCR3 + CCR4- T cells (up/down) 0.007 0.604
Injection site reaction (Grade2/ 0.145 0.003
Continuous vaccination after PD (Yes/No) - 0.007